In This Article:
For the quarter ended March 2025, TransMedics (TMDX) reported revenue of $143.54 million, up 48.2% over the same period last year. EPS came in at $0.70, compared to $0.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $123.56 million, representing a surprise of +16.17%. The company delivered an EPS surprise of +141.38%, with the consensus EPS estimate being $0.29.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Geographic Revenues- All other countries: $4.07 million compared to the $4.21 million average estimate based on four analysts. The reported number represents a change of -0.6% year over year.
-
Geographic Revenues- United States: $138.62 million versus the four-analyst average estimate of $119.11 million. The reported number represents a year-over-year change of +50.9%.
-
Net revenue by OCS product- OCS Lung net revenue: $4.01 million versus the four-analyst average estimate of $5.19 million. The reported number represents a year-over-year change of -29.2%.
-
Net revenue by OCS product- OCS Liver net revenue: $108.86 million versus $87.87 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +62.7% change.
-
Net revenue by OCS product- OCS Heart net revenue: $29.82 million compared to the $30.01 million average estimate based on four analysts. The reported number represents a change of +27.8% year over year.
View all Key Company Metrics for TransMedics here>>>
Shares of TransMedics have returned +27.1% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TransMedics Group, Inc. (TMDX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).